Healthy volunteers test new injection in Early-Stage drug study
NCT ID NCT06895967
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This completed Phase 1 trial studied how the body absorbs and clears two different subcutaneous immunoglobulin therapies, TAK-881 and HyQvia, in 30 healthy adults aged 18-50. Participants received a single injection and were monitored for 85 days. The goal was to compare the pharmacokinetics of the two treatments, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.